NeoGenomics Inc has a consensus price target of $20.46, established from looking at the 63 latest analyst ratings. The last 3 analyst ratings were released from Piper Sandler, Goldman Sachs, and Needham on February 26, 2024, February 22, 2024, and February 21, 2024. With an average price target of $21 between Piper Sandler, Goldman Sachs, and Needham, there's an implied 33.59% upside for NeoGenomics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/26/2024 | NEO | Buy Now | NeoGenomics | $15.72 | 27.23% | Piper Sandler | David Westenberg | $18 → $20 | Maintains | Overweight | Get Alert |
02/22/2024 | NEO | Buy Now | NeoGenomics | $15.72 | 20.87% | Goldman Sachs | Matthew Sykes | $17 → $19 | Maintains | Buy | Get Alert |
02/21/2024 | NEO | Buy Now | NeoGenomics | $15.72 | 52.67% | Needham | Mike Matson | $21 → $24 | Maintains | Buy | Get Alert |
12/29/2023 | NEO | Buy Now | NeoGenomics | $15.72 | 20.87% | TD Cowen | Dan Brennan | $22 → $19 | Maintains | Outperform | Get Alert |
12/29/2023 | NEO | Buy Now | NeoGenomics | $15.72 | 33.59% | BTIG | Mark Massaro | $25 → $21 | Maintains | Buy | Get Alert |
12/28/2023 | NEO | Buy Now | NeoGenomics | $15.72 | 33.59% | Needham | Mike Matson | → $21 | Reiterates | Buy → Buy | Get Alert |
11/08/2023 | NEO | Buy Now | NeoGenomics | $15.72 | 8.14% | Morgan Stanley | Tejas Savant | $16 → $17 | Maintains | Equal-Weight | Get Alert |
11/07/2023 | NEO | Buy Now | NeoGenomics | $15.72 | 33.59% | Needham | Mike Matson | → $21 | Reiterates | Buy → Buy | Get Alert |
10/24/2023 | NEO | Buy Now | NeoGenomics | $15.72 | 1.78% | Morgan Stanley | Tejas Savant | $18 → $16 | Maintains | Equal-Weight | Get Alert |
10/23/2023 | NEO | Buy Now | NeoGenomics | $15.72 | 8.14% | Goldman Sachs | Matthew Sykes | $19 → $17 | Maintains | Buy | Get Alert |
10/20/2023 | NEO | Buy Now | NeoGenomics | $15.72 | 8.14% | Goldman Sachs | Matthew Sykes | $19 → $17 | Maintains | Buy | Get Alert |
10/16/2023 | NEO | Buy Now | NeoGenomics | $15.72 | 14.5% | Piper Sandler | David Westenberg | $23 → $18 | Maintains | Overweight | Get Alert |
08/21/2023 | NEO | Buy Now | NeoGenomics | $15.72 | 14.5% | Stephens & Co. | Jacob Johnson | $16 → $18 | Upgrade | Equal-Weight → Overweight | Get Alert |
08/09/2023 | NEO | Buy Now | NeoGenomics | $15.72 | 14.5% | Benchmark | Bruce Jackson | $20 → $18 | Maintains | Buy | Get Alert |
08/09/2023 | NEO | Buy Now | NeoGenomics | $15.72 | 14.5% | Morgan Stanley | Tejas Savant | $19 → $18 | Maintains | Equal-Weight | Get Alert |
08/09/2023 | NEO | Buy Now | NeoGenomics | $15.72 | 33.59% | Needham | Mike Matson | → $21 | Reiterates | Buy → Buy | Get Alert |
05/16/2023 | NEO | Buy Now | NeoGenomics | $15.72 | — | Raymond James | Andrew Cooper | — | Downgrade | Outperform → Market Perform | Get Alert |
05/10/2023 | NEO | Buy Now | NeoGenomics | $15.72 | 20.87% | Morgan Stanley | Tejas Savant | $18 → $19 | Maintains | Equal-Weight | Get Alert |
05/09/2023 | NEO | Buy Now | NeoGenomics | $15.72 | 59.03% | BTIG | Mark Massaro | → $25 | Upgrade | Neutral → Buy | Get Alert |
The latest price target for NeoGenomics (NASDAQ: NEO) was reported by Piper Sandler on February 26, 2024. The analyst firm set a price target for $20.00 expecting NEO to rise to within 12 months (a possible 27.23% upside). 24 analyst firms have reported ratings in the last year.
The latest analyst rating for NeoGenomics (NASDAQ: NEO) was provided by Piper Sandler, and NeoGenomics maintained their overweight rating.
The last upgrade for NeoGenomics Inc happened on August 21, 2023 when Stephens & Co. raised their price target to $18. Stephens & Co. previously had an equal-weight for NeoGenomics Inc.
The last downgrade for NeoGenomics Inc happened on May 16, 2023 when Raymond James changed their price target from N/A to N/A for NeoGenomics Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeoGenomics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeoGenomics was filed on February 26, 2024 so you should expect the next rating to be made available sometime around February 26, 2025.
While ratings are subjective and will change, the latest NeoGenomics (NEO) rating was a maintained with a price target of $18.00 to $20.00. The current price NeoGenomics (NEO) is trading at is $15.72, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.